Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with endogenous Cushing's syndrome, meaning the body itself makes too much cortisol. They will have a PET/CT scan with 68Ga-DOTA-mDesmo to find the tumor.

Életkor

5 to 75 years

Nem

All sexes

A betegség stádiuma

Endogenous Cushing's syndrome (too much cortisol made by the body itself)

A részvétel fő kizáró okai

• Cushing's syndrome caused by steroid medicines taken from outside the body
• Current pregnancy
• Severe other illnesses that may interfere with the study

A regiszter feltételei, szó szerint

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

• 5 és 75 év között vagy?IgenNem

Mit akar kideríteni a vizsgálat

The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases. Among these, nearly 90% of ACTH-dependent CS are due to pituitary-dependent CS, known as Cushing disease (CD). The management of ACTH-dependent CS relies on distinguishing Cushing disease (or Corticotropinoma) from ectopic Cushing syndrome (ECS) followed by localization of the tumor in the sella. The diagnosis of CD is very challenging, especially when they are microadenomas (<6 mm). Current imaging techniques, such as magnetic resonance imaging (MRI), have limitations in accurately delineating (sensitivity 60%) these tumors. Even if the lesion is detected inside the pituitary, the functionality of the tumor is questionable, as there can be innocent pituitary tumors which actually are not the cause of Cushing syndrome in a particular case. The diagnosis gets more complex with the fact that 10% of the ECS cases are reported to have an incidental non-functioning pituitary tumor, this can complicate the diagnosis of ECS. Though the localizing accuracy of bilateral inferior petrosal sinus sampling (BIPSS) is 90%, the lateralization (40-70%) of corticotropinoma (whether the lesion is located on the right or left side) based on BIPSS is still questionable. These challenges contribute to the fact that in approximately 30% of cases of CD, the source of ACTH excess remains occult. The lack of information on accurate localization and lateralization of corticotropinoma leads to reduced remission rates after surgery. Therefore, novel approaches to diagnosing Cushing disease are needed.

A vizsgálat csoportja

• Patients with cushing syndrome (CS) characterized by excessive cortisol secretion in the body

  To detect and localize the tumor responsible for ACTH-dependent CS. For deleneation of small tumors within the pituitary. Ga-68mDesmo will be injected to enable PET/CT imaging. Ga-68 is a positron emitter.